Opdivo
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved Opdivo with Yervoy for the first-line treatment of adult patients with unresectable or ...
APRIL 14, 2025
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
The FDA has approved Opdivo with Yervoy for unresectable or metastatic microsatellite instability−high or ...
APRIL 9, 2025
FDA Approves Neoadjuvant/Adjuvant Opdivo for Resectable NSCLC
The FDA approved Opdivo with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent ...
OCTOBER 4, 2024
FDA Approves Opdivo Combination for Unresectable or Metastatic Urothelial Carcinoma
The FDA approved nivolumab Opdivo in combination with cisplatin and gemcitabine for first-line treatment of adult ...
MARCH 8, 2024
FDA Approves Opdivo for Adjuvant Treatment of Select Patients With Stage IIB/C Melanoma
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) for the adjuvant treatment of completely resected stage ...
OCTOBER 17, 2023
Pharmacokinetics May Help Optimize Dosing of ICIs
Flat and extended-interval dosing of some immune checkpoint inhibitor (ICI) drugs can be used in certain ...
APRIL 14, 2022
Nivolumab Indicated as Neoadjuvant NSCLC Treatment
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with platinum-doublet chemotherapy to ...
APRIL 12, 2022
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb (BMS) has voluntarily withdrawn from the U.S. market the ...
JULY 27, 2021
FDA Grants New Indication for Opdivo for Resected Esophageal or GEJ Cancer
The FDA granted a new indication for nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of patients with ...
JUNE 7, 2021
Opdivo Approved for First-Line Treatment of Advanced or Metastatic GI Cancers
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb), in combination with fluoropyrimidine- and ...
APRIL 27, 2021
FDA Grants New Indication for Opdivo + Yervoy Combo in mCRC
The FDA granted a new indication for Opdivo and Yervoy to treat adults and children 12 years of age and older with ...
JULY 12, 2018
FDA Grants Opdivo New Indication for HCC Patients Previously Treated With Sorafenib
The U.S. burden of hepatocellular carcinoma is significant. A recent ACS report noted that death rates from liver ...
OCTOBER 2, 2017